← All trials
NCT05055232
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2019
- Primary completion
- Mar 12, 2023
- Completion date
- Sep 12, 2023
- First posted
- Sep 24, 2021
- Last posted
- Sep 24, 2021
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xuanzhu Biopharmaceutical Co., Ltd.Lead sponsor
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.